DE07776925T1 - Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums - Google Patents

Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums Download PDF

Info

Publication number
DE07776925T1
DE07776925T1 DE07776925T DE07776925T DE07776925T1 DE 07776925 T1 DE07776925 T1 DE 07776925T1 DE 07776925 T DE07776925 T DE 07776925T DE 07776925 T DE07776925 T DE 07776925T DE 07776925 T1 DE07776925 T1 DE 07776925T1
Authority
DE
Germany
Prior art keywords
calcium
crystalline form
atorvastatin hemi
storage
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE07776925T
Other languages
English (en)
Other versions
DE07776925T8 (de
Inventor
Judith Aronhime
Ramy Lindor-Hadas
Valerie Niddam-Hildesheim
Shlomit Wizel
Revital Lifshitz-Liron
Michael Pinchasov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of DE07776925T1 publication Critical patent/DE07776925T1/de
Application granted granted Critical
Publication of DE07776925T8 publication Critical patent/DE07776925T8/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Kristalline Form von Atorvastatin-Hemi-Calcium, gekennzeichnet durch ein Pulverröntgenbeugungsmuster mit Peaks bei 6,9, 9,3, 9,6, 16,3, 17,1, 19,2, 20,0, 21,6, 22,4, 23,9, 24,7, 25,6 und 26,5 ± 0,2 Grad 2θ, die gegen die Bildung von Atorvastatin-calciumepoxydihydroxy (AED) stabil ist.

Claims (8)

  1. Kristalline Form von Atorvastatin-Hemi-Calcium, gekennzeichnet durch ein Pulverröntgenbeugungsmuster mit Peaks bei 6,9, 9,3, 9,6, 16,3, 17,1, 19,2, 20,0, 21,6, 22,4, 23,9, 24,7, 25,6 und 26,5 ± 0,2 Grad 2θ, die gegen die Bildung von Atorvastatin-calciumepoxydihydroxy (AED) stabil ist.
  2. Kristalline Form von Atorvastatin-Hemi-Calcium nach Anspruch 1, welche nach Lagerung bei einer Temperatur von etwa 40°C bei einer relativen Feuchte von etwa 75% für wenigstens etwa einen Monat weniger als etwa 0,01% (w/w) AED enthält.
  3. Kristalline Form von Atorvastatin-Hemi-Calcium nach Anspruch 1, welche nach Lagerung bei einer Temperatur von etwa 25°C bei einer relativen Feuchte von etwa 60% für wenigstens etwa 6 Monate weniger als etwa 0,01% (w/w) AED enthält.
  4. Kristalline Form von Atorvastatin-Hemi-Calcium nach einem der Ansprüche 1 bis 3, welche ein Isopropanolat oder ein Ethanolat ist.
  5. Pharmazeutische Zusammensetzung, welche das Atorvastatin-Hemi-Calcium nach einem der vorangegangenen Ansprüche umfaßt.
  6. Kristallines Atorvastatin-Hemi-Calcium nach einem der Ansprüche 1 bis 4 zur Verwendung in der Therapie.
  7. Kristallines Atorvastatin-Hemi-Calcium nach einem der Ansprüche 1 bis 4 zur Verwendung beim Reduzieren von Cholesterol oder LDL.
  8. Verwendung eines kristallinen Atorvastatin-Hemi-Calciums nach einem der Ansprüche 1 bis 4 für die Herstellung eines Medikaments zum Reduzieren von Cholesterol oder LDL.
DE07776925T 2006-05-09 2007-05-08 Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums Active DE07776925T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/431,183 US20070265456A1 (en) 2006-05-09 2006-05-09 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US20060431183 2006-05-09
PCT/US2007/011236 WO2007133597A1 (en) 2006-05-09 2007-05-08 Crystalline form of atorvastatin calcium stable after storage

Publications (2)

Publication Number Publication Date
DE07776925T1 true DE07776925T1 (de) 2008-07-03
DE07776925T8 DE07776925T8 (de) 2009-04-30

Family

ID=38512661

Family Applications (1)

Application Number Title Priority Date Filing Date
DE07776925T Active DE07776925T8 (de) 2006-05-09 2007-05-08 Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums

Country Status (11)

Country Link
US (1) US20070265456A1 (de)
EP (1) EP2024331A1 (de)
JP (2) JP2009500429A (de)
KR (1) KR20080015510A (de)
CN (1) CN101437791A (de)
BR (1) BRPI0702876A2 (de)
CA (1) CA2649708A1 (de)
DE (1) DE07776925T8 (de)
ES (1) ES2312307T1 (de)
IL (1) IL194876A0 (de)
WO (1) WO2007133597A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74075C2 (en) * 2001-06-29 2005-10-17 Warner Lambert Co NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI0848705T1 (en) * 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
EP1480950A4 (de) * 2002-02-15 2005-05-18 Teva Pharma Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium
CA2475123A1 (en) * 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2575243A1 (en) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
TWI321132B (en) * 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities

Also Published As

Publication number Publication date
ES2312307T1 (es) 2009-03-01
IL194876A0 (en) 2009-08-03
CA2649708A1 (en) 2007-11-22
WO2007133597A1 (en) 2007-11-22
US20070265456A1 (en) 2007-11-15
CN101437791A (zh) 2009-05-20
JP2009500429A (ja) 2009-01-08
WO2007133597A9 (en) 2008-01-24
DE07776925T8 (de) 2009-04-30
BRPI0702876A2 (pt) 2011-03-15
JP2007302665A (ja) 2007-11-22
KR20080015510A (ko) 2008-02-19
EP2024331A1 (de) 2009-02-18

Similar Documents

Publication Publication Date Title
Singh et al. Investigating TiO2–HA–PCL hybrid coating as an efficient corrosion resistant barrier of ZM21 Mg alloy
DE07776925T1 (de) Kristalline Form eines nach der Lagerung stabilen Atorvastatin-Calciums
DE13156663T1 (de) NRF2-Screening-Assays sowie entsprechende Verfahren und Zusammensetzungen
EP2135628A3 (de) Stent mit einer Beschichtung oder einem Grundkörper, der ein Lithiumsalz enthält, und Verwendung von Lithiumsalzen zur Restenoseprophylaxe
DE01998348T1 (de) Neue kristallformen von atorvastatin-hemicalcium und verfahren zu ihrer herstellung sowie neue verfahren zur herstellung anderer formen
NZ599889A (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
WO2006114415A2 (de) Physiologisch verträgliche salze von 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
Kebiroglu et al. Temperature dependent structural and vibrational properties of hydroxyapatite: A theoretical and experimental study
JP2013536825A5 (de)
CA2649022A1 (en) Cocrystal of c-glycoside derivative and l-proline
ATE97809T1 (de) Verwendung von 5-methyltetrahydrofolsaeure, 5formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe und wirksam in der therapie organisch mentaler stoerungen sowie die entsprechenden arzneimittel.
BR0309167A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação
DE14721256T1 (de) Pharmazeutische zusammensetzungen mit kristallinem macitentan
DE502006004182D1 (de) Substituierte 5,6,7,8-tetrahydro-imidazoä1 ,2-aüpyridin-2-ylamin-verbindungen und deren verwendung zur herstellung von arzneimitteln
RU2492163C9 (ru) Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии
EP1738781A3 (de) Verwendung von Propolis als Beschichtungmaterial für medizinische Implantate
DE05774589T1 (de) Neue kristallformen von atorvastatin-hemi-calcium und verfahren zu deren herstellung
EP1803777A3 (de) Vernetzbare Massen auf der Basis von Organosiliciumverbindungen
EP1421929A3 (de) Emollients und kosmetische Zubereitungen
DE346013C (de) Harte, in der Form unveraenderliche, unzerbrechliche und leicht bearbeitbare Gegenstaende, welche gegen X-Strahlen und radioaktive Strahlen undurchlaessig sind
CN1899046A (zh) 抗菌密胺材料及其制备方法和在餐具中的应用
DE102014113177B4 (de) Verfahren zur Herstellung eines Bauteils und Abutment
JP2012511571A5 (de)
EP2336103A3 (de) HCL-Polymorphe von 3-[2-(Dimethylamino)methyl-(cyclohex-1-yl)]phenol
CH699087A1 (de) Implantat.

Legal Events

Date Code Title Description
8596 Reprint of erroneous front page